Clinical Trial

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

Name: Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing — clinical trial record (NCT07281014)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The purpose of this research study is to understand the biology related to the potential shortcomings of existing anti-aldosterone therapy.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-03.

Status change: Not Yet Recruiting → Recruiting 2026-02-16

Trial Details

NCT Number	NCT07281014
Lead Sponsor	Yale University Collaborators: Boehringer Ingelheim
Conditions	Heart Failure
Enrollment	20 participants
Start Date	2026-01-27
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-02-19